Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News GlaxoSmithKline announces new HIV/Aids commitments

GlaxoSmithKline announces new HIV/Aids commitments

15th July 2009

GlaxoSmithKline has announced a range of new initiatives and commitments to help people with HIV and Aids.

In a statement, the pharmaceutical company explained that the new schemes will focus on the treatment and care of young people with the conditions.

One of the initiatives is a new Positive Action For Children Fund, which will offer a total of 50 million pounds over a period of ten years to help prevent mother-to-child transmission of HIV, as well as offering aid to orphans and other vulnerable kids.

Andrew Witty, chief executive officer of GlaxoSmithKline, commented on the move while speaking at the Action Zingatia Maisha HIV programme in Kenya.

He said the firm should make use of its expertise as a company capable of carrying out world-class research to develop new therapies for HIV and Aids.

“We will therefore make available ten million pounds as seed money to support a new public-private partnership approach for paediatric HIV research,” Mr Witty concluded.

Earlier this year, GlaxoSmithKline and Pfizer announced an agreement to create a new company dedicated to the commercialisation of new HIV therapies.

We currently have 9 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.